Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 1:30 p.m. PT / 4:30 p.m. ET. The presentation will showcase the company's advancements in translating the genetics of the adaptive immune system into clinical products for disease diagnosis and treatment. Interested individuals can access a live and archived webcast via the company’s website. Adaptive Biotechnologies focuses on developing immune-driven clinical products aimed at treating various diseases including cancer and autoimmune conditions.

SEATTLE, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 39^th Annual J.P. Morgan Healthcare Conference.

Adaptive Biotechnologies’ management is scheduled to present on Monday, January 11^th at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.

About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

FAQ

When is Adaptive Biotechnologies presenting at the J.P. Morgan Healthcare Conference?

Adaptive Biotechnologies will present on January 11, 2021, at 1:30 p.m. PT / 4:30 p.m. ET.

How can I watch the Adaptive Biotechnologies presentation at the conference?

You can access the live and archived webcast of the presentation on the Investors section of their website.

What does Adaptive Biotechnologies focus on?

The company focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating diseases.

What diseases does Adaptive Biotechnologies aim to treat?

They aim to treat diseases such as cancer, autoimmune conditions, and infectious diseases.

What stock symbol is associated with Adaptive Biotechnologies?

The stock symbol for Adaptive Biotechnologies is ADPT.